Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: A systematic review

S. Hassan, A. Cannavò, S. C. Gouw, F. R. Rosendaal, J. G. van der Bom

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Essentials: Data on product-related immunogenicity in previously treated haemophilia A patients is scarce. A systematic review and meta-analysis of all currently available evidence was conducted. The overall incidence rate was 2.06 per 1000 person-years (95% confidence interval: 1.06-4.01). Some recombinant factor VIII products were associated with increased immunogenicity. Summary: Background: Patients with severe hemophilia A who have been treated extensively with factor VIII products have a low but potentially serious risk of inhibitor development. It is unknown why these patients develop inhibitors, and data on product-related immunogenicity are scarce. Aims: To summarize the currently available evidence on the relationship between inhibitor development and recombinant FVIII product type in previously treated patients (PTPs) with severe hemophilia A. Methods: Longitudinal studies were included that reported on de novo inhibitor formation in patients with baseline FVIII activity levels of < 0.02 IU mL-1 who had been treated with FVIII for at least 50 days. Pooled incidence rates of inhibitor development according to product types were calculated with a random intercept Poisson regression model. Results: Forty-one independent cohorts were included; 39 patients developed de novo inhibitors during 19 157 person-years of observation. The overall incidence rate was 2.06 per 1000 person-years, with a 95% confidence interval (CI) of 1.06-4.01. According to product type, the pooled incidence rates were 0.99 (95% CI 0.37-2.70) per 1000 person-years for patients treated with Advate, 5.86 (95% CI 0.25-134.92) per 1000 person-years for those treated with Kogenate/Helixate, 1.35 (95% CI 0.66-2.77) per 1000 person-years for those treated with Kogenate FS/Helixate NexGen, 12.05 (95% CI 1.53-94.78) per 1000 person-years for those treated with Refacto, and 4.64 (95% CI 0.82-26.43) per 1000 person-years for those treated with Refacto AF. Conclusion: These results suggest that some products may be associated with increased immunogenicity. However, the low incidence of inhibitors in PTPs and the differences in study design may cause significant variation in estimates of risk.

Original languageEnglish
Pages (from-to)1055-1068
JournalJournal of Thrombosis and Haemostasis
Volume16
Issue number6
DOIs
Publication statusPublished - 2018

Fingerprint

Factor VIII
Hemophilia A
Confidence Intervals
Incidence
Longitudinal Studies
Meta-Analysis
Observation

Keywords

  • Factor VIII
  • Hemophilia A
  • Meta-analysis
  • Neutralizing antibodies
  • Risk factors

ASJC Scopus subject areas

  • Hematology

Cite this

Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A : A systematic review. / Hassan, S.; Cannavò, A.; Gouw, S. C.; Rosendaal, F. R.; van der Bom, J. G.

In: Journal of Thrombosis and Haemostasis, Vol. 16, No. 6, 2018, p. 1055-1068.

Research output: Contribution to journalArticle

@article{2dabe5650dee4732914d46e870ce6696,
title = "Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: A systematic review",
abstract = "Essentials: Data on product-related immunogenicity in previously treated haemophilia A patients is scarce. A systematic review and meta-analysis of all currently available evidence was conducted. The overall incidence rate was 2.06 per 1000 person-years (95{\%} confidence interval: 1.06-4.01). Some recombinant factor VIII products were associated with increased immunogenicity. Summary: Background: Patients with severe hemophilia A who have been treated extensively with factor VIII products have a low but potentially serious risk of inhibitor development. It is unknown why these patients develop inhibitors, and data on product-related immunogenicity are scarce. Aims: To summarize the currently available evidence on the relationship between inhibitor development and recombinant FVIII product type in previously treated patients (PTPs) with severe hemophilia A. Methods: Longitudinal studies were included that reported on de novo inhibitor formation in patients with baseline FVIII activity levels of < 0.02 IU mL-1 who had been treated with FVIII for at least 50 days. Pooled incidence rates of inhibitor development according to product types were calculated with a random intercept Poisson regression model. Results: Forty-one independent cohorts were included; 39 patients developed de novo inhibitors during 19 157 person-years of observation. The overall incidence rate was 2.06 per 1000 person-years, with a 95{\%} confidence interval (CI) of 1.06-4.01. According to product type, the pooled incidence rates were 0.99 (95{\%} CI 0.37-2.70) per 1000 person-years for patients treated with Advate, 5.86 (95{\%} CI 0.25-134.92) per 1000 person-years for those treated with Kogenate/Helixate, 1.35 (95{\%} CI 0.66-2.77) per 1000 person-years for those treated with Kogenate FS/Helixate NexGen, 12.05 (95{\%} CI 1.53-94.78) per 1000 person-years for those treated with Refacto, and 4.64 (95{\%} CI 0.82-26.43) per 1000 person-years for those treated with Refacto AF. Conclusion: These results suggest that some products may be associated with increased immunogenicity. However, the low incidence of inhibitors in PTPs and the differences in study design may cause significant variation in estimates of risk.",
keywords = "Factor VIII, Hemophilia A, Meta-analysis, Neutralizing antibodies, Risk factors",
author = "S. Hassan and A. Cannav{\`o} and Gouw, {S. C.} and Rosendaal, {F. R.} and {van der Bom}, {J. G.}",
year = "2018",
doi = "10.1111/jth.14124",
language = "English",
volume = "16",
pages = "1055--1068",
journal = "Journal of Thrombosis and Haemostasis",
issn = "1538-7933",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A

T2 - A systematic review

AU - Hassan, S.

AU - Cannavò, A.

AU - Gouw, S. C.

AU - Rosendaal, F. R.

AU - van der Bom, J. G.

PY - 2018

Y1 - 2018

N2 - Essentials: Data on product-related immunogenicity in previously treated haemophilia A patients is scarce. A systematic review and meta-analysis of all currently available evidence was conducted. The overall incidence rate was 2.06 per 1000 person-years (95% confidence interval: 1.06-4.01). Some recombinant factor VIII products were associated with increased immunogenicity. Summary: Background: Patients with severe hemophilia A who have been treated extensively with factor VIII products have a low but potentially serious risk of inhibitor development. It is unknown why these patients develop inhibitors, and data on product-related immunogenicity are scarce. Aims: To summarize the currently available evidence on the relationship between inhibitor development and recombinant FVIII product type in previously treated patients (PTPs) with severe hemophilia A. Methods: Longitudinal studies were included that reported on de novo inhibitor formation in patients with baseline FVIII activity levels of < 0.02 IU mL-1 who had been treated with FVIII for at least 50 days. Pooled incidence rates of inhibitor development according to product types were calculated with a random intercept Poisson regression model. Results: Forty-one independent cohorts were included; 39 patients developed de novo inhibitors during 19 157 person-years of observation. The overall incidence rate was 2.06 per 1000 person-years, with a 95% confidence interval (CI) of 1.06-4.01. According to product type, the pooled incidence rates were 0.99 (95% CI 0.37-2.70) per 1000 person-years for patients treated with Advate, 5.86 (95% CI 0.25-134.92) per 1000 person-years for those treated with Kogenate/Helixate, 1.35 (95% CI 0.66-2.77) per 1000 person-years for those treated with Kogenate FS/Helixate NexGen, 12.05 (95% CI 1.53-94.78) per 1000 person-years for those treated with Refacto, and 4.64 (95% CI 0.82-26.43) per 1000 person-years for those treated with Refacto AF. Conclusion: These results suggest that some products may be associated with increased immunogenicity. However, the low incidence of inhibitors in PTPs and the differences in study design may cause significant variation in estimates of risk.

AB - Essentials: Data on product-related immunogenicity in previously treated haemophilia A patients is scarce. A systematic review and meta-analysis of all currently available evidence was conducted. The overall incidence rate was 2.06 per 1000 person-years (95% confidence interval: 1.06-4.01). Some recombinant factor VIII products were associated with increased immunogenicity. Summary: Background: Patients with severe hemophilia A who have been treated extensively with factor VIII products have a low but potentially serious risk of inhibitor development. It is unknown why these patients develop inhibitors, and data on product-related immunogenicity are scarce. Aims: To summarize the currently available evidence on the relationship between inhibitor development and recombinant FVIII product type in previously treated patients (PTPs) with severe hemophilia A. Methods: Longitudinal studies were included that reported on de novo inhibitor formation in patients with baseline FVIII activity levels of < 0.02 IU mL-1 who had been treated with FVIII for at least 50 days. Pooled incidence rates of inhibitor development according to product types were calculated with a random intercept Poisson regression model. Results: Forty-one independent cohorts were included; 39 patients developed de novo inhibitors during 19 157 person-years of observation. The overall incidence rate was 2.06 per 1000 person-years, with a 95% confidence interval (CI) of 1.06-4.01. According to product type, the pooled incidence rates were 0.99 (95% CI 0.37-2.70) per 1000 person-years for patients treated with Advate, 5.86 (95% CI 0.25-134.92) per 1000 person-years for those treated with Kogenate/Helixate, 1.35 (95% CI 0.66-2.77) per 1000 person-years for those treated with Kogenate FS/Helixate NexGen, 12.05 (95% CI 1.53-94.78) per 1000 person-years for those treated with Refacto, and 4.64 (95% CI 0.82-26.43) per 1000 person-years for those treated with Refacto AF. Conclusion: These results suggest that some products may be associated with increased immunogenicity. However, the low incidence of inhibitors in PTPs and the differences in study design may cause significant variation in estimates of risk.

KW - Factor VIII

KW - Hemophilia A

KW - Meta-analysis

KW - Neutralizing antibodies

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=85047455089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047455089&partnerID=8YFLogxK

U2 - 10.1111/jth.14124

DO - 10.1111/jth.14124

M3 - Article

AN - SCOPUS:85047455089

VL - 16

SP - 1055

EP - 1068

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

SN - 1538-7933

IS - 6

ER -